Vanguard Health Care Fund Investor Shares
VGHCX
NASDAQ- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Vanguard Health Care Fund (VGHCX) is an open-end mutual fund that invests primarily in equity securities of companies located in the health care sector worldwide. The fund offers investors exposure to a diversified portfolio including biotechnology, pharmaceuticals, health care providers and services, health care technology, life sciences tools and services, and medical devices; it may also allocate to other sectors when deemed appropriate by its management team. Managed by The Vanguard Group, Inc., headquartered in Malvern, Pennsylvania, and founded in 1976, the fund operates globally with a focus on U.S.-listed securities while holding positions in international health care firms. Vanguard Health Care Fund serves long-term investors seeking capital appreciation through active management by experienced portfolio managers who select stocks based on fundamental analysis, growth potential, and valuation metrics. The fund maintains a portfolio of approximately 100-150 holdings, with top positions typically featuring leading companies such as Eli Lilly and Company, UnitedHealth Group Incorporated, and Thermo Fisher Scientific Inc.; it employs a bottom-up stock selection process emphasizing innovative therapies, demographic-driven demand for health care, and resilient business models. Assets under management stand at around $50 billion as of late 2025, reflecting steady inflows amid sector tailwinds like aging populations and advancements in gene therapy and precision medicine. The fund's expense ratio remains competitively low at 0.35%, characteristic of Vanguard's investor-first approach. In recent developments, the fund benefited from Vanguard's broader strategic initiatives, including the 2024 launch of enhanced ESG integration options for health care sector funds and a partnership expansion with institutional advisors to improve distribution in emerging markets such as Asia-Pacific. Portfolio managers executed key repositionings in 2025, increasing allocations to obesity treatment innovators and AI-driven diagnostics firms following strong clinical trial outcomes; additionally, the fund participated in Vanguard's acquisition of a minority stake in a leading biotech index provider to bolster proprietary research capabilities. These changes align with ongoing adaptations to regulatory shifts in drug pricing and telehealth expansion, positioning the fund for sustained outperformance relative to the MSCI World Health Care Index benchmark.